regorafenib

{
  "id": "MLC-T-ONC-007310",
  "term": "regorafenib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat certain types of colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma (a type of liver cancer). It is also being studied in the treatment of other types of cancer. Regorafenib blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Regorafenib is a type of kinase inhibitor and a type of antiangiogenesis agent. Also called Stivarga.",
    "The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling."
  ],
  "synonyms": [
    "Stivarga",
    "multikinase inhibitor BAY 73-4506",
    "regorafenib anhydrous"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/regorafenib/"
}